PD 166285

PD 166285 is a tyrosine kinase inhibitor. It inhibits Src, FGFR1, EGFR, and PDGFRbeta (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM). PD 166285 inhibits PDGF- or EGF-induced receptor autophosphorylation in vascular smooth muscle cells (VSMCs) and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively). It also inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM). PD 166285 inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells. In vivo, PD 166285 (1, 5, and 10 mg/kg) inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with photodynamic therapy (PDT).Formal Name: 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one, dihydrochloride. CAS Number: 212391-63-4. Molecular Formula: C26H27Cl2N5O2 . 2HCl. Formula Weight: 585.4. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: soluble. lambdamax: 214, 263, 300, 365 nm. SMILES: ClC1=CC=CC(Cl)=C1C2=CC3=CN=C(NC4=CC=C(OCCN(CC)CC)C=C4)N=C3N(C)C2=O.Cl.Cl. InChi Code: InChI=1S/C26H27Cl2N5O2.2ClH/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28,,/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31),2*1H. InChi Key: NADLBPWBFGTESN-UHFFFAOYSA-N.